Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Tamoxifen on Mutant Allele Burden in Myeloproliferative Neoplasms
2015-005497-38Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen in myeloproliferative disorder (MPD), sponsored by University of Birmingham. Primary endpoint: Primary molecular response at 24 weeks. Status: unknown.
02
Drugs
tamoxifen
03
Conditions
myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on 2015-005497-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005497-38.